Castrated male rats were treated with the reversible S 1 -phase cell cycle blocking drug, mimosine, and the effects of this drug on prostate cell apoptosis was characterized. At a single dose of mimosine (25 mg/kg/day), we found that the internucleosomal DNA fragmentation associated with apoptosis was partially suppressed in the rat ventral prostate at all early time points (24, 48 and 72 h) analyzed post-castration. This suppression was dose-dependent, and treatment with mimosine up to 150 mg/kg/day was sufficient to reduce the internucleosomal DNA fragmentation in the prostate by 90% at 72 h post-castration. Intriguingly, this drug did not suppress the induction of mRNAs for several apoptosis-associated gene products in the ventral prostate gland (bcl-2, p53, TGF-b and SGP-2/clusterin). Moreover, this treatment did not suppress the histological appearance of apoptotic bodies in the ventral prostate detectable by fast green staining of thin sections of tissue. The apoptotic bodies present in mimosinetreated regressing ventral prostate tissues, however, were refractory to labeling by the in situ gap labeling method, further demonstrating lack of nuclear DNA fragmentation in the condensed nuclei of apoptotic cells. In summary, the cell cycle-blocking drug mimosine does not appear to affect the rate of apoptosis in the regressing rat ventral prostate gland. However, this drug was capable of suppressing the nuclear DNA fragmentation associated with androgen-regulated prostate cell apoptosis. These results support the concept that nuclear DNA fragmentation is not obligatory for apoptosis. Additionally, they imply that cell cycle movement from the G 1 /S-phase boundary might be important for the terminal DNA degradation associated with androgen-regulated prostate cell apoptosis.
Introduction
The ventral prostate gland of the rat has provided an ideal in vivo model system to study the cellular, biochemical and molecular events associated with apoptosis (Colombel and Buttyan, 1995) . In a mature male, this tissue will lose up to 85% of its cellular population within the 2 weeks following castration (Berges et al, 1993) . The secretory epithelial cells of this organ are highly dependent on testosterone and castration initiates the onset of their apoptosis in a very predictable manner (Sanford et al, 1984) . Like many other in vitro cell models of apoptosis, the androgen-deprived prostate epithelial cell undergoes a series of morphological and biochemical changes exemplified by cytoplasmic blabbing, nuclear condensation and pyknosis in conjunction with internucleosomal degradation of the nuclear DNA (Colombel and Buttyan, 1995) . As with other apoptotic systems, the nuclear DNA degradation is easily visualized by the detection of a prototypic DNA`ladder' following agarose gel electrophoresis of DNA extracted from a regressing rat prostate gland. The DNA fragmentation can also be recognized in situ in fixed regressing rat prostate tissues by any of a number of immunohistochemical staining techniques that detect the enzymatic incorporation of chemically-modified nucleotides into fragmented DNA by exogenous DNA polymerase or terminal transferase.
Early experiments indicated that this in vivo system of apoptosis is, at least partially, dependent on RNA and protein synthesis (Lee, 1981) . More recently, a large number of studies have demonstrated that several specific mRNAs and proteins are induced in the apoptotic prostate cell (Colombel and Buttyan, 1995) . Since some of these apoptosis-induced gene products are linked to cell cycle progression (for examples c-myc, PCNA, p53), it has been proposed that there is some cell cycle movement in prostate epithelial cells associated with androgen deprivation that is important for the onset of apoptosis (Buttyan et al, 1988; Colombel et al, 1992; Zhang et al, 1994) . Specifically, since many of these same gene products are induced prior to or at the G 1 /S boundary, the suggestion has been put forth that androgen-dependent prostate cell apoptosis occurs in conjunction with cell transition to the early S-phase of the cell cycle (Buttyan, 1991) . This is a controversial hypothesis (Colombel et al, 1992) and one that has been relatively difficult to test because androgendependent apoptosis is only known to occur in certain tissues in vivo. One test of this hypothesis would be to treat castrated male rats with an agent that is known to inhibit cell cycle progression, especially in the early stage, and determine the effects of such treatment on prostate cell apoptosis.
For this reason, we chose to test the effects of a novel drug, mimosine [b-N (3-hydroxy-4-pyridone) a-amino propionic acid] on the characteristic parameters of apoptosis in the regressing ventral prostate glands of male rats. This drug is a non-proteinogenic amino acid naturally occurring in the legume genera Mimosa and Leucaena (Thompson et al, 1969) . We felt it was an appropriate agent for these experiments because several in vitro studies have established that it reversibly blocks the cell cycle at or near the G 1 /S boundary (Watson et al, 1991) . Secondly, unlike other cell-cycle blocking agents, this drug is not known to be extensively metabolized by the liver or other tissues. Finally, mimosine has already been shown effective in suppressing cell proliferation, in vivo, in a dose-dependent manner when administered to rodents (Crounse et al, 1962) . The results presented here demonstrate that this agent, while not blocking the apoptotic process in the androgen-deprived rat prostate gland, does affect at least one important phenotypic characteristic of the apoptotic cell, namely, the prototypic internucleosomal DNA fragmentation that is commonly associated with apoptosis. Since it is now better understood that this drug blocks cells at the beginning of the S-phase (Hughes and Cook, 1996) , this suggsts that DNA metabolic activity within the S-phase might be important for the DNA fragmentation associated with this type of apoptosis.
Results and Discussion
Internucleosomal DNA fragmentation is suppressed in the regressing rat prostate gland by mimosine treatment
One of the most characteristic markers for apoptosis is a prototypic pattern of nuclear DNA degradation that results in the generation of nuclear DNA fragments in multiples of approximately 180 bp (Kyprianou and Isaacs, 1988) . This degradation pattern is often attributed to the activation of endogenous nucleases associated with the onset of apoptosis that digest DNA primarily in the internucleosomal regions. When DNA from tissues containing apoptotic cells (such as the regressing rat ventral prostate gland) is electrophoresed on an agarose gel, the DNA fragments migrate in a characteristic pattern described as a ladder because of the regular series of bands generated by DNA fragments in multiples of the 180 bp motif. This DNA ladder is readily demonstrated in Figure 1 , where DNA was extracted from rat ventral prostate specimens obtained at 1, 2 and 3 days after castration, electrophoresed on a 1.5% agarose gel and stained with ethidium bromide. In DNA extracted from prostate tissues obtained at comparable times from castrated rats that were treated with mimosine (oral supplementation 25 mg/kg/day), however, the intensity of the DNA ladder is decreased and densitometric evaluation of the film negative taken from this gel suggest a 30 ± 50% reduction in DNA fragments at the three different time points with mimosine treatment. An additional dose-escalation experiment involving intraperitoneal administration of mimosine established that the suppression of internucleosomal DNA fragmentation by this drug was dose dependent. Figure 2 shows an ethidium bromide-stained agarose gel of DNAs extracted from ventral prostate tissues obtained from 3 day castrated rats that had been treated with mimosine in sequentially increasing doses. At the highest treatment dose (150 mg/kg/day, i.p.), mimosine effectively suppressed the appearance of DNA fragments by 90% as estimated by densitometric analysis of the film negative taken on this gel. If this prototypical DNA fragmentation was used as the only criterion identifying apoptosis in regressing prostate tissue, these results would suggest that mimosine treatment was highly effective in suppressing androgen-dependent apoptosis.
Mimosine does not inhibit protein syntheses in the regressing rat prostate gland
Previous studies have determined that regression of the rat ventral prostate gland can be suppressed by protein synthesis inhibitors (Lee, 1981) . Although the mechanism of action of mimosine has been reported to be more related to its iron-chelating effects (Dai et al, 1994) , this substance is an a-amino acid analogue. Therefore, we wanted to determine whether the suppression of nuclear DNA fragmentation in the regressing prostate gland by this drug might be due to its effects on protein synthesis. To ensure that mimosine treatment is not specifically inhibiting protein synthesis in regressing rat prostate gland, we measured the in vivo incorporation of [
35 S]-methionine into proteins extracted from the regressing glands of mimosine-treated
Figure 1 Mimosine treatment (25 mg/day, orally) suppresses apoptotic DNA fragmentation in the regressing ventral prostate glands of castrated rats. Electrophoretic analysis of DNA extracted from mimosine-treated (M-) and -untreated (C-) rat ventral prostate glands at various times after castration (24, 48 and 72 h, as indicated). Aliquots of DNAs (10 ugs) extracted from tissues, as indicated, were co-electrophoresed on a 1.5% agarose gel. The gel was stained with ethidium bromide and photographed directly under ultraviolet light. Compared to untreated rats, mimosine treatment suppressed the appearance of the DNA fragmentation ladder at all time points after castration.
and -untreated rats. One group of rats received 150 mg/kg/ day of mimosine for 48 h subsequent to castration. Control rats without mimosine were simply castrated and subsequently maintained under normal conditions for 48 h. Both groups then received a bolus of [ 35 S]-methionine administered intravenously. Two hours later, all rats were sacrificed and the regressing ventral prostates were removed and processed to determine the extent of incorporation of the radiolabeled methionine into TCA-precipitable proteins. We found that there was no difference in the amount of radiolabeled methionine incorporation in the regessing prostate glands between these two groups of rats (mimosine-treated 3.01+0.30610 3 cpm/mg tissue vs 2.4+0.61610 3 cpm/mg tissue in the untreated group) (n=6 for each group, no significant difference between these groups). Our results indicated that mimosine treatment did not significantly affect [
35 S]-methionine incorporation by the regressing rat prostate gland. Thus, the suppression of internucleosomal DNA fragmentation in the regressing prostate glands of mimosine-treated rats was not a generalized result of a suppression of protein synthesis by this drug.
Effect of mimosine on the apoptosis-associated gene expression in the regressing rat ventral prostate gland
To determine whether mimosine altered other biochemical characteristics associated with apoptosis in the regressing ventral prostate gland, we analyzed RNAs extracted from these tissues for the expression of gene products that were previously shown to be induced after castration. RNase protection assays were used to evaluate the relative amounts of TGF-b, p53, bcl-2 and SGP-2/clusterin mRNAs in control rat ventral prostate gland and in regressing ventral prostate glands obtained at 72 h post-castration, with or without mimosine treatment. As was previously reported (Zhang et al, 1994; Kyprianou and Issacs, 1989; Buttyan et al, 1989; McDonnell et al, 1992) , all of these mRNAs are significantly elevated in the post-castrated ventral prostate when compared to the amount expressed in control prostate tissue (Figure 3 ). Mimosine treatment did not affect the apparent degree of induction for any of these mRNA species. The apparent lack of effect of mimosine on the induced expression of these gene products is in contrast to the results obtained in the DNA fragmentation experiments and suggests that other characteristic parameters of apoptosis are unaltered by mimosine treatment.
Mimosine treatment inhibits the detection of apoptotic bodies by ISGL
In situ gap labeling (ISGL) is one version of a familiar combined enzymatic/immunohistochemical technique that enables the detection of cell nuclei with fragmented DNA in thin sections of fixed tissues (Meyaard et al, 1992 ; Wijsman , 1993) . This technique takes advantage of the ability of Klenow DNA polymerase to fill gaps in degraded nuclear DNA with digoxigenin-modified nucleotides. Labeled DNA in apoptotic cell nuclei can then be easily detected by an immunohistochemical staining procedure with monoclonal anti-digoxigenin antibody conjugated to alkaline phosphatase. We utilized this technique to stain sections of ventral prostate tissue obtained from untreated 60 h castrated rats or from mimosine-treated 60 h castrated rats (150 mg/kg/ day, i.p.). Following the immunohistochemical stain, the sections were counterstained with fast-green. Microscopic analysis of these tissues showed that the fast-green counterstain was sufficient to identify the presence of overt apoptotic bodies in both untreated and mimosinetreated regressing prostate tissues (Figure 4 ). These were recognized by their shrunken appearance and by their distinct separation from neighboring epithelial cells. However, remarkably, the nuclei of the apoptotic bodies in mimosine-treated specimens were refractory to staining by the ISGL technique (Figure 4) , suggesting that the apoptotic process was ongoing in this tissue in the absence of the extensive nuclear DNA fragmentation usually associated with androgen-regulated prostate cell apoptosis. The results of this in situ detection method supports our DNA analytical experiments in showing that mimosine treatment suppressed the DNA fragmentation associated with prostate regression. However, based on our ability to identify apoptotic bodies by simple histochemical staining methods and to detected apoptosis-induced gene activity in mimosine-treated regressing prostate glands, the suppression of DNA fragmentation was not sufficient to inhibit the actual occurrence of apoptosis in the prostate gland. Previously, a similar cell cycle blocking agent, hydroxyurea was tested for its effects on rat prostate cell apoptosis (Berges et al, 1993) . The action of hydroxyurea is believed to be due to its inhibitory action against ribonucleotide reductase and a subsequent depletion of the intracellular deoxynucleotide triphosphate pool (Gilbert et al, 1995) . Based on its mode of action, hydroxyurea likely allows complete transition through the G 1 phase, but S-phase (as defined by DNA synthesis) cannot begin. Simple analysis of cell loss from the prostate gland after castration showed no difference between hydroxyureatreated and -untreated rats and it was concluded that cell cycle movement was not relevant for apoptosis in this situation (Berges et al, 1993 ). Here, we tested another cell cycle blocking drug, mimosine, that likely acts in a similar manner to hydroxyurea in suppressing cell cycle movement at the S-phase. Some of the most recent biochemical characterization of this substance suggests that it, like hydroxyurea, blocks the formation of replication forks of DNA in dividing cells (Gilbert et al, 1995) , most likely by inhibiting deoxyribonucleotide metabolism. Indeed, mimosine has already proven to be an apoptosis-blocking drug when tested against NGF depleted PC12 cells (Farinelli and Green, 1996) . In this situation, coordinate studies with drugs other than mimosine seem to confirm that G 1 ?Sphase movement is important for certain neuronal cell deaths.
In our experiments, mimosine treatment of rats did not apparently suppress or alter the rate of androgen-withdrawal based apoptosis of prostate epithelial cells. These results are similar to those reported for hydroxyurea treatment of castrated rats, a drug which may act in a similar mechanism to mimosine in suppressing cell cycle movement at the early S phase. Likewise, mimosine did not suppress the induced expression of certain gene products in the castrated rat prostate, many of which are important for the movement of cells through the G 1 phase of the cell cycle. Given that neither of these drugs prevent movement of the cell cycle through the late G 1 phase to the S-phase, their failure to block androgen-regulated apoptosis in the rat prostate gland is not sufficient evidence that early cell cycle movement is not involved in the mechanism of these cell deaths. It is still possible that some events associated with the mid-to-late G 1 phase transition of the cell cycle are critical for the actual cell death mechanism involved in the prostate cells' response to androgen deprivation. It should be noted that mimosine did, however, strikingly affect some characteristics of apoptosis in these prostate cells, potently suppressing the appearance of nuclear DNA fragmentation. This may indicate that some aspect of replicative DNA synthesis, previously described in association with prostate regression (Colombel et al, 1992) is involved in the internucleosomal DNA fragmentation that accompanies prostate cell apoptosis. It will be interesting in the future to determine whether hydroxyurea treatment suppresses DNA fragmentation in this model system of apoptosis or whether this is a specific effect of mimosine. Likewise, it is likely to require novel agents that suppress cell cycle movement through the late G 1 phase to ultimately test this hypothesis.
Materials and Methods

Animals and tissues
Mature male Sprague-Dawley rats (325 ± 350 g) were purchased from Camm, INN (Camden, New Jersey) and maintained with food and water ad libitum as recommended by the National Institute of Health Guidelines for the Care and Use of Laboratory Animals. Rats were surgically castrated as previously described (Zhang et al, 1994) . Mimosine (Sigma, St Louis, MO) was administered by two methods, as indicated. Oral dosing was achieved by measuring the daily water intake of rats over the period of a week and then adding the drug to the water so that the expected daily intake would be 25 mg/kg/day. Alternatively, rats were injected, i.p. at daily intervals with an aqueous solution of mimosine to deliver the described dosage. Rats were sacrificed at the indicated times by a overdose of sodium pentobarbital, i.p., and the ventral prostate glands were removed. These tissues were flash-frozen in liquid nitrogen and stored in 7808C for subsequent processing.
Detection of ventral prostate gland DNA fragmentation
Frozen ventral prostate tissues from treated/untreated castrated rats were pulverized under liquid nitrogen. DNA was extracted from 50 mg frozen tissue powder using the ASAP genomic DNA extraction kit (Boehringer Mannheim Biochemicals, Indianapolis, IN) as previously described (Colombel et al, 1992) and was quantitated by spectrophotometer at 260 nm. Aliquots containing 10 mg of genomic DNA from each specimen were then electrophoresed on a 1.5% agarose gel. The gel was photographed under ultraviolet light subsequent to staining with ethidium bromide. The film negative obtained from these photos was analyzed by densitometry (Molecular Dynamics Scanning Densitometer) for the relative density of the second and third bands from the bottom of the DNA ladder to quantitatively compare the amount of DNA fragmentation between mimosine-treated anduntreated specimens.
RNA extraction and analysis
Frozen rat ventral prostate tissues were pulverized under liquid nitrogen and then the total RNA was extracted with the use of the RNAzole B regent (TelTest, Inc, Friendswood, TX) as previously described (Zhang et al, 1994) . Small cDNA fragments for bcl-2 were obtained by PCR amplification of oligo-dT primed, reverse transcribed RNA from rat ventral prostate gland using PCR primers designed by a software analysis program, Oligo 4.0 (National Biosciences, Hameln, MN), applied to the known sequence of human bcl-2 in Genebank (Tsujimoto and Croce, 1986) . The PCR primers for rat TGF-b1 were purchased from Clonetech, Inc (Palo Alto, CA). Amplified DNA fragments were cloned into the TA II cloning vector (Invitrogen, San Diego, CA) and sequenced using standard didoxunucleotide methods. Riboprobe expression vectors for rat p53, SGP-2 and GAPDH were previously described (Zhang et al, 1994) . Ribonuclease protection Figure 4 In situ-gap labeling (ISGL) method used ot detect fragmented DNA in apoptotic cells of the regressing rat ventral prostate gland fails to identify apoptotic bodies in mimosine-treated rats. (A) Thin sections of ventral prostates obtained from rats at 60 h after castration were stained using the ISGL enzymatic-immunohistochemical labeling technique with an alkalinephosphatase detection system. Nuclei of apoptotic bodies (arrows) are darkly stained by this technique. Tissue is counterstained with fast green. (B) Thin sections of ventral prostates obtained from rats at 60 h after castration with mimosine treatment (150 mg/day) were refractory to ISGL staining. Apoptotic bodies could be detected in these tissues with the fast green counter stain (arrows), but their nuclei were not labeled by this technique. assay was performed as described (Zhang et al, 1994) using RPA II ribonuclease protection assay kit from Ambion, Inc (Austin, TX). Briefly, riboprobes were synthesized from plasmid by T7 or SP6 RNA polymerase using [ 32 P]-UTP and aliquots containing 2610 5 cpm antisense gel purified riboprobes were hybridized with 20 mg aliquots of total RNA extracted from control and experimental rat ventral prostate glands overnight at 458C and followed by RNase treatment for 30 min at 378C. Digests were applied to 8% acrylamide sequencing gels and then was exposed to X-ray film to produce an autoradiography. Densitometry was performed on films, when indicated, with the Molecular Dynamics Scanning Laser Densitometer.
In situ-gap labeling (ISGL) of fragmented DNA and histologic identi®cation of apoptotic bodies
Regressing ventral prostate glands (60 h after castration) from mimosine-treated and-untreated rats were fixed in 4% paraformaldehyde in phosphate-buffered saline overnight, then soaked in 25% sucrose, phophate-buffered saline for 12 to 24 h. The tissues were dehyrated and embedded in paraffin blocks using standard conditions. Thin sections (5 mm) were cut from the blocks and stained by the In Situ-Gap Labeling procedure as previously described (Santarosa et al, 1994) . Briefly, rehydrated tissues were digested in 0.1 M sodium acetate, pH 2.0 containing 0.1% pepsin for 30 min at 378C. Slides were washed and incubated with 50 mM Tris-HCl (pH 7.5), 5 mM MgCl 2 , 10 mM 2-mercaptoethanol, and 0.005% bovine serum albumin containing 1 mM dATP, dTTP, dGTP, 100 mM digoxigenin-labeled dUTP and 100 units/ml of Klenow DNA polymerase (Boehringer Mannheim Biochemicals, Indianapolis, IN) at 158C for 30 min. The slides were then washed in 0.1 M sodium maleate and treated with a blocking solution from Boehringer Mannheim, Inc. (Indianapolis, IN), then incubated with alkaline phosphatase-conjugated monoclonal mouse anti-digoxigenin antibody from Boehringer Mannheim, Inc. (Indianapolis, IN) for 45 min at 378C. Alkaline phosphatase activity was detected with substrates 5-bromo-4-chloro-3-indolylphosphate rtoluidine, and nitroblue tetrazolium chloride (NBT). Tissues were lightly counterstained with methylene green, dehydrated and mounted for photomicroscopy.
Effect of mimosine on protein synthesis in the regressing prostate gland A group of six rats was castrated and subsequently treated with mimosine at 150 mg/day (i.p. injection) for 48 h. Control rats (n=6) were castrated for 48 h but received no mimosine treatment. Control and treated rats then received a bolus of 0.5 mCi [
35 S]-methionine (Amersham Inc., Arlington Heights, IL) administered by i.v. injection into the femoral vein. Two hours later, all rats were sacrificed and ventral prostate tissue was recovered, weighed and pulverized to a fine powder under liquid nitrogen for subsequent extraction and quantitation of radiolabeled [
35 S] content. The powder was homogenized in a buffer containing 25 mM Tris-HCl (pH 7.5), 1mM EDTA, and 0.5% Triton X-100 for 2 min with Polytron Homogenizer (Brinkmann Instruments, Inc., Westbury, NY). Aliquots of 250, 150 and 50 mls were precipitated in ice cold 5% TCA (Maniatis et al, 1982) . The precipitate was collected by filtering the solution through a GF/C glassfiber filter in a Whatman vacuum filtration apparatus (Whatman International Ltd, Maidstone, England). Filters were washed five times with 5% TCA followed by 95% ethanol, air dried and then placed into vials with liquid scintillation fluid. 
